RETA Reata Pharmaceuticals Inc.

+0.04  (0%)
Previous Close 32.95
Open 32.90
Price To book -3.74
Market Cap 707.63M
Shares 22,365,000
Volume 118,278
Short Ratio 7.95
Av. Daily Volume 141,297

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Data from Phase 2 part of trial released July 24, 2017. Phase 3 data due 2H 2019.
Bardoxolone methyl - CARDINAL
Chronic Kidney Disease Caused by Alport Syndrome
Phase 2 enrollment commenced January 2017. Data due 2H 2017.
Bardoxolone methyl - LARIAT
Pulmonary hypertension due to interstitial lung disease - PH-ILD
Phase 3 commenced enrollment October 2016 with data due 2H 2018.
Bardoxolone methyl - CATALYST
Pulmonary arterial hypertension associated with connective tissue disease - CTD-PAH
Phase 2 initial data released June 1, 2017. Primary endpoint not met. Part 2 due to be enroll 2H 2017.
Omaveloxolone - MOXIe
Friedreich’s ataxia (FA)
Phase 2 initial data due 2H 2017.
Omaveloxolone - MOTOR
Mitochondrial myopathies (MM)
Phase 1b portion of trial due 2H 2017.
Omaveloxolone - REVEAL
Metastatic melanoma

Latest News

  1. Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Omaveloxolone for the Treatment of Malignant Melanoma
  2. Reata Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : RETA-US : September 1, 2017
  3. ETFs with exposure to Reata Pharmaceuticals, Inc. : September 1, 2017
  4. Featured Company News - Sorrento Submits NDA for ZTlido Next-Gen Lidocaine Patch; Intends to File an MAA in Europe
  5. Reata Pharmaceuticals, Inc. :RETA-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
  6. Reata Pharmaceuticals, Inc. – Value Analysis (NASDAQ:RETA) : August 15, 2017
  7. Reata Pharmaceuticals, Inc. Announces Second Quarter 2017 Financial and Operating Results
  8. FDA Confirms That Use of mFARS as Primary Endpoint in Part 2 of the MOXIe Trial Can Support Approval of Omaveloxolone in Friedreich’s Ataxia
  9. Reata Announces First Patient Enrolled in Phase 3 CARDINAL Trial of Bardoxolone Methyl in the Treatment of Chronic Kidney Disease Due to Alport Syndrome
  10. Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
  11. Reata Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RETA-US : August 1, 2017
  12. Reata Pharmaceuticals, Inc. Announces Pricing of Class A Common Stock Public Offering
  13. Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock
  14. Why Reata Pharmaceuticals Is Rallying 17.5% Today
  15. Reata Pharma Greenlights Phase 3 in Chronic Kidney Disease Trial
  16. Reata’s Bardoxolone Methyl Demonstrated Improved Kidney Function in Patients With Alport Syndrome in Ongoing Phase 2 Portion of Phase 2/3 Cardinal Study
  17. ETFs with exposure to Reata Pharmaceuticals, Inc. : June 22, 2017
  18. Here Comes a Big Breakout For Alibaba